EYEN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 09:54):

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology...

Stats
Today's Volume	107 775
Average Volume	1.21M
Market Cap	27.24M
EPS	$0 ( 2024-03-18 )
Next earnings date	( $-0.250 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.820
ATR14	$0.00600 (1.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Grant Stuart M.	Buy	100 000	Common stock, par value $0.0001
2024-03-19	Grant Stuart M.	Buy	50 000	Common stock, par value $0.0001
2024-03-08	Grant Stuart M.	Buy	10 717	Common stock, par value $0.0001
2024-02-12	Gandolfo John P	Buy	60 000	Stock Option (right to buy)
2024-02-12	Rowe Michael M	Buy	75 000	Stock Option (right to buy)

INSIDER POWER
69.24
Last 95 transactions
Buy: 2 919 948 \| Sell: 334 000

Volume Correlation

Long: -0.32 (neutral)

Short: 0.08 (neutral)

Signal:(46.205) Neutral

Eyenovia Inc Correlation

10 Most Positive Correlations
WINA	0.968
INZY	0.966
AMTBB	0.961
CSPI	0.955
TAYD	0.95
SVFAU	0.948
SVFA	0.947
HROW	0.946
BRLI	0.944
HSKA	0.944

10 Most Negative Correlations
CYRN	-0.957
TLGT	-0.936
GNTY	-0.935
FVCB	-0.934
ONEM	-0.933
RPRX	-0.93
PEAR	-0.93
VORB	-0.929
BWB	-0.929
AROW	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Eyenovia Inc Correlation - Currency/Commodity

-0.41
( neutral )

0.54
( weak )

0.00
( neutral )

-0.71
( moderate negative )

0.00
( neutral )

0.70
( moderate )

Eyenovia Inc Financials

Annual	2023
Revenue:	$3 787.00
Gross Profit:	$-783 208 (-20 681.49 %)
EPS:	$-0.660

Q4	2023
Revenue:	$2 589.00
Gross Profit:	$-277 524 (-10 719.35 %)
EPS:	$-0.180

Q3	2023
Revenue:	$1 198.00
Gross Profit:	$0 (0.00 %)
EPS:	$-0.180

Q2	2023
Revenue:	$0
Gross Profit:	$-271 209 (0.00 %)
EPS:	$-0.160

Financial Reports:

No articles found.

Eyenovia Inc

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.